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Abstract 
Background: Acute Coronary Syndrome (ACS) is currently diagnosed using a 12-lead 
Electrocardiogram (ECG). Our recent work however has shown that interpretation of 
the 12-lead ECG is complex and that clinicians can be sub-optimal in their 
interpretation.  Additionally, ECG does not always identify acute total occlusions in 
certain patients. 
 
Purpose: The aim of the present study was to compare protein expression profiles of 
ACS patients, to detect biomarkers that may improve the diagnosis of ACS or augment 
ECG interpretation. 
 
Methods: Patients were recruited consecutively at the cardiac catheterization 
laboratory at Altnagelvin Hospital over a period of 6 months.  A low risk control group 
was recruited by advertisement. Blood samples were analysed using the multiplex 
proximity extension assays by OLINK proteomics.  Support vector machine (SVM) 
learning was used as a classifier to distinguish between patient groups on training data.  
The ST segment elevation level was extracted from each ECG for a subset of patients 
and combined with the protein markers. Quadratic SVM (QSVM) learning was then 
used as a classifier to distinguish STEMI from NSTEMI on training and test data. 
 
Results: Of the 344 participants recruited, 77 were initially diagnosed with NSTEMI, 
7 with STEMI, and 81 were low risk controls. The other participants were those 
diagnosed with angina (stable and unstable) or non-cardiac patients. Of the 368 proteins 
analysed, 20 proteins together could significantly differentiate between patients with 
ACS and patients with stable angina (ROC-AUC=0.96). Six proteins discriminated 
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significantly between the stable angina and the low risk control groups (ROC-
AUC=1.0). Additionally, 16 proteins together perfectly discriminated between the 
STEMI and NSTEMI patients (ROC-AUC=1). ECG comparisons with the protein 
biomarker data for a subset of patients (STEMI n=6 and NSTEMI n=6), demonstrated 
that 21 features (20 proteins + ST elevation) resulted in the highest classification 
accuracy 91.7% (ROC-AUC= 0.94). The 20 proteins without the ST elevation feature 
gave an accuracy of 80.6% (ROC-AUC 0.91), while the ST elevation feature without 
the protein biomarkers resulted in an accuracy of 69.3% (ROC-AUC=0.81). 
 
Conclusions: Although patient numbers for the STEMI group were low in this analysis, 
results showed that certain panels of proteins could stratify patients and may be a useful 
to aid in the diagnosis of ACS. This preliminary analysis reveals the potential for blood 
biomarkers to augment ECG interpretation. 
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Introduction 
The diagnosis of Acute Coronary Syndrome (ACS) has traditionally relied upon the 12-
lead ECG in combination with ischemic symptoms and elevation in serum biomarkers. 
However, symptoms are often atypical or absent, and around 33% of patients that 
present with ACS may not have chest pains [1]. Similarly, ECG changes that aid with 
early diagnosis may be nonspecific or even absent in around 40% of the patients [2]. 
Acute total occlusion of the culprit artery usually presents with ST-elevation 
myocardial infarction, however a subset of patients with acute total occlusion present 
as non-ST segment elevation myocardial infarction (NSTEMI) [3,4].  The inability of 
the ECG to identify these patients may lead to delay in their proper 
management. Moreover, ST-segment changes are also observed in other cardiac 
conditions like pericarditis, left ventricular hypertrophy, cardiomyopathies and 
channelopathies, which can add to the diagnostic dilemma.   
 
Our recent work has shown that interpretation of the 12-lead ECG is complex and that 
clinicians are sub-optimal in their interpretation [5,6]. For example, up to 33% of ECG 
interpretations contain errors of significant importance. In addition, as a result of our 
recent eye tracking studies we have found that even expert clinicians are known to 
impulsively provide a diagnosis based on their first impression and can, as a result, miss 
co-abnormalities [7,8]. Whilst the human interpretation of the ECG needs 
improvement, computerised automatic interpretation of the ECG remains very poor – 
often less accurate in comparison to cardiologists [9,10]. Computerised ECG 
interpretation is a very complex and challenging task that requires effective signal 
processing, statistical analysis and often artificial intelligence. These algorithms as 
reported in the literature [10] are often inaccurate which is a concern given clinical staff 
are biased towards the machine diagnosis which often results in false positives [7,8]. 
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Other diagnostic methods rely on measurements of High Sensitivity Cardiac Troponin 
T (HScTnT), which is the only accepted blood biomarker for ACS diagnosis. However, 
there is a delay between symptom onset and detectable levels of troponin in the blood 
and it often requires repeated measurements over time to be of value [11]. Thus, 
additional blood markers have been sought in order to improve the initial diagnosis and 
also to help risk stratification. The discovery of new blood biomarkers could not only 
improve the diagnosis of ACS, but also provide insights into the underlying 
pathophysiology [12,13]. In the last decade, a few circulating biomarkers, such as Heart 
fatty acid binding protein (H-FABP) and N-terminal pro-brain natriuretic peptide (NT-
proBNP) have been investigated [14]. Currently there is no consensus on the best 
cardiac biomarker or combination of those studied as standalone or adjunctive 
diagnostic. It would be helpful if a panel of markers could improve the confidence of 
the interpreter of the ECG whilst at the same time improve accuracy of the diagnosis. 
Blood biomarkers are being sought that can help diagnose ACS by evidencing heart 
muscle damage and/or be indicative of an acute total occlusion of a culprit artery. The 
latter is especially important given that such occlusions occur in NSTEMI ECG 
patients, whom are often not triaged for urgent catheterization.  We currently lack well-
validated high performing markers that not only diagnose ACS but classify/stratify 
patients based on angiographic findings (complete acute occlusions of the culprit artery 
or not). This is of major importance when triaging patients for the correct activation of 
the pPCI pathway. However, as long as this is not possible, the STEMI/NSTEMI 
categorization predominates the triage.  
 
We therefore undertook a multiplex proteomics approach to investigate whether a blood 
protein biosignature could improve ACS diagnosis. We primarily wanted to investigate 
whether certain blood protein biomarkers could discriminate between ACS and non-
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ACS patients. As an exploratory analysis, we used a machine learning approach to 
investigate if blood biomarkers could augment or improve the accuracy of the ECG 
diagnosis of ACS and in particular STEMI diagnosis in a subset of our patients.  
 
 
Methods 
Participant recruitment  
Acute or elective patient admissions were recruited consecutively from the 
catheterisation laboratory at Altnagelvin Hospital. Acute MI was diagnosed when either 
initial or 12 h cTnT was ≥14ng/L, with or without ECG features of 
ischaemia/infarction, in the absence of any other cause for the chest pain. If this 
definition was met then classification was made into ST-segment elevation MI 
(STEMI) and non-STEMI (NSTEMI). The diagnosis of STEMI required ST-segment 
elevation in at least two contiguous leads of the ECG or new onset of left bundle branch 
block. ST-segment elevation was defined as ≥1 mm in leads I–III, aVL, aVF, V4, V5, 
and V6 and ≥2 mm in leads V1–V3. Categorization of patients as NSTEMI was by 
exclusion of STEMI and elevation in serum troponin with confirmatory angiographic 
evidence of obstructive coronary artery disease. An elective group of patients with 
documented coronary artery disease attending the catheterisation laboratory for 
coronary angiogram or PCI were also recruited. A low risk control group who had a 
10-year fatal CVD risk <10% according to the European Systematic Coronary Risk 
Evaluation (SCORE) were recruited by advertisement to Hospital and University staff.  
 
Each patient provided informed written consent. Blood samples were collected prior to 
coronary angiography. After discarding the first 5mls of blood to avoid unnecessary 
biological activation blood was drawn (8mls) and dispensed into tubes which were then 
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immediately cooled and centrifuged (within 4 hours of collection) at 2000 RCF for 15 
minutes. Plasma and buffy coat were aliquoted and frozen at −80◦C until further 
analysis. The ECG which classified patients as STEMI or NSTEMI was logged. 
Demographic information as well as previous medical and clinical history was 
collected. The blood pressure was recorded at the time along with C-Reactive Protein 
(CRP) and electrolytes levels on the same day. The research protocol was approved by 
the Office for Research Ethics Committees Northern Ireland (ORECNI) 
(Ref:14/NI/0068). Each participant gave informed written consent. 
 
Proteomic profiling 
Plasma samples were assessed with the Proseek Multiplex proximity extension assay 
(Olink Bioscience, Uppsala, Sweden). The assay simultaneously measures 92 proteins 
in each panel using two specific antibodies per protein that pairwise bind to each 
protein, creating a polymerase chain reaction sequence. This is followed by quantitative 
real-time polymerase chain reaction for quantification. The CVDII, CVDIII, 
inflammatory and immune response panels were used with a total measurement of 368 
proteins.  
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Data analysis 
All data analytics were carried out using MATLAB (https://www.mathworks.com/). To 
build classifiers without ECG, we ranked individual proteins by the Area Under the 
Curve (AUC) of the Receiver Operator Characteristic (ROC) curve obtained when 
patient groups were classified by Support Vector Machines (SVM) with a linear kernel. 
Starting with the best individual protein, we built multivariate classifiers using subsets 
of the top performing individual proteins. In order to evaluate the expected overfitting 
in each classifier, rather than segregate the data into training and validation subsets and 
lose statistical power, instead we randomly relabelled the patients between groups to 
generate nonsense data.  Relabelling occurred until the nonsense data was uncorrelated 
with the original data.  This was repeated twenty times to yield twenty nonsense data 
sets.  The same classifiers were built from the nonsense data and the mean of the AUCs 
based on the nonsense data was calculated as a benchmark against which to assess 
classifiers for true data.  
 
To build classifiers we used Quadratic Support Vector Machine (QSVM) with 
quadratic kernel function, with the ECG and a subset of differentially expressed 
proteins. To assess the accuracy of the classifier, ROC curves were developed to obtain 
cumulative AUCs for increasing numbers of proteins in the panel, based on the 
minimum number of most significant proteins required for accurate classification. ST 
segment elevation level was extracted from each ECG and combined with the protein 
biomarkers dataset. Pearson-correlation coefficients function were used for feature 
selection (biomarkers dataset + ST level) to compute P-values to find the optimal set of 
features to determine STEMI/NSTEMI patients. QSVM was used as a classifier to 
detect STEMI and NSTEMI. We applied 12-fold cross-validation since we had a 
limited number of STEMI patients. In QSVM we started with the most important 
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features (39 features including 38 biomarkers and ST elevation level) and then we 
removed feature by feature to get the highest accuracy. Multivariate analysis was 
carried out to account for confounding factors including age and gender. 
 
 
Results  
Patient recruitment 
A total of 344 patients were recruited including ACS (STEMI n=7 and NSTEMI n=77), 
Unstable Angina (n=21), Elective coronary artery disease (CAD) (n=158) patients and 
low risk controls (n=81). (Table 1). The mean age of the patients at study entry was 65 
years and 21% were women. A total of 56% had a history of hypertension, 19% were 
diabetic and 19% were current smokers. A total of 55.4% (n=127) of CAD patients 
were admitted with an ACS and 44.4% (n=102) were electively admitted for coronary 
angiogram. The mean age of the control participants was 46 years and 70% were 
women. A total of 13% had hypertension and 4% were current smokers. The mean age 
of the low risk group was 41 years and 79% were women. The average time from 
admission to blood sampling for  patients was 3 days. 
 
Blood biomarker analysis for ACS diagnosis 
Blood plasma levels of 368 proteins were analysed using protein extension assays by 
Olink Proteomics. These multiplex arrays were employed to identify biomarkers in 
patients with ACS, CAD patients attending for a coronary angiogram or PCI and low 
risk individuals (apparently healthy controls). Baseline characteristics of these patients 
are shown in Table 1. Of the 344 participants recruited, 77 were diagnosed with 
NSTEMI, 7 with STEMI, and 81 were low risk controls. The other participants were 
those diagnosed with angina (stable and unstable) or non-cardiac patients. Of the 368 
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proteins analysed, 20 proteins could significantly differentiate between ACS patients 
and all other participants in the cohort (ROC=0.95) (Fig 1a). Further analysis showed 
that 20 proteins could significantly differentiate between patients with ACS and 
patients with stable angina (ROC=0.96) (Fig 1b). We also found that any one of 6 
particular proteins were significantly different between the elective patients with CAD 
and the low risk control group (ROC=1.0) (Fig 1c). Additionally, 16 proteins were 
significantly discriminating between the STEMI and NSTEMI patients (ROC=1) (Fig 
1d). It is of note that due to intellectual property constraints the proteins can not yet be 
named. 
 
Blood biomarker and ECG for STEMI diagnosis 
A subset of 12 patients (6 STEMI and 6 NSTEMI) were randomly selected for 
exploratory analysis to investigate if protein profiles could augment ECG diagnosis for 
ACS. ECG comparisons with the protein biomarker data for a subset of patients 
(STEMI n=6 and NSTEMI n=6), demonstrated that 21 features (20 proteins + ST 
elevation) resulted in the highest classification accuracy 91.7% (ROC-AUC= 0.94) (fig. 
2a). The 20 proteins without the ST elevation feature gave an accuracy of 80.6% (ROC-
AUC 0.91) (fig. 2b), while the ST elevation feature without the protein biomarkers 
resulted in an accuracy of 69.3% (ROC-AUC=0.81) (fig. 2c). 
 
 
Discussion 
ACS is often a diagnostic dilemma, primarily due to problems/limitations associated 
with 1) variability in patient history/symptoms, 2) accuracy and timings of serum 
biomarker measurements 3) ECG accuracy due to both the machine and human 
interpretation and 4) ECG can be inherently limited to what is presented (surface ECG 
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is just that). Incorrect diagnosis of ACS has significant consequences for patient safety 
and the health service. Internationally an average of 15% of patients that come to the 
catheterization lab are defined as false activations [15] (the patient was not suffering a 
myocardial infarction). This has significant health economic cost implications, a 
significant impact on the staff in terms of fatigue and workflow within the department 
particularly if the activation has occurred during the night and exposes the patient to 
the risk of doing an invasive procedure that could have been avoided if the clinical 
decision-making was better. Additionally, those patients that are not correctly referred 
for pPCI have poorer outcomes [16]. There is a need therefore to develop better ways 
to improve clinical decision making for deciding upon the initial treatment strategy for 
ACS patients. 
 
In this study we measured multiple blood protein biomarkers in consecutive patients 
recruited at the cath lab. A low risk control group with no identifiable risk factors were 
also included in our analysis. This multiplex approach combined with SVM learning 
allowed us to identify a panel of proteins that could significantly identify the ACS 
patients in our cohort. Importantly we also identified panels of proteins that 
significantly differed between ACS and elective stable angina patients. A panel of other 
markers also significantly differed when comparing these elective patients with the low 
risk control group. These latter proteins are of significant importance since they appear 
to be specific for CAD and not only increased due to a non-specific acute phase 
response. To date most studies have concentrated on looking at markers of heart muscle 
damage and myocyte load to assess ACS [14]. Other markers are emerging, including 
those relating to inflammation, oxidative stress and fibrosis, which are pivotal in 
cardiovascular disease [14-18]. These studies have also used multiplex technology to 
aid progress in this area. These studies however so far have only measured proteins in 
relatively small numbers of STEMI patients in comparison to either healthy controls or 
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individuals at CVD risk.  To the best of our knowledge no one has taken a multiplex 
approach comparing larger numbers of patients in all ACS categories (STEMI, 
NSTEMI, UA) and compared these with stable angina or a low risk scored control 
group. It is important to note that this is a pilot study that was set up to identify 
differences between the 3 main patient groups (ACS, stable CAD and low risk). A 
major limitation of this current study is that the average time from admission to blood 
sampling for patients was 3 days. Future validation work is therefore required with 
regards to timings of blood samples. These markers therefore need to be measured over 
time to fully ascertain their diagnostic value and investigate potential confounders in 
this current study such as treatment that may have commenced prior to blood sampling. 
In addition, these results will need to be replicated in a validation cohort with larger 
numbers of STEMI patients. 
 
We also undertook a preliminary analysis in a subset of our patients using another 
machine learning approach. QSVM demonstrated that 20 blood proteins could improve 
the ECG accuracy for STEMI detection from 69.3% (ROC-AUC=0.81) to 91.7% 
(ROC-AUC= 0.94). This is purely an exploratory analysis and although patient 
numbers are low and the blood samples analysed were obtained on average 3 days after 
the cardiac event, a statistically significant difference was observed in proteins between 
STEMI and NSTEMI patients. These results are still under investigation, but some 
previous research has suggested that certain plasma proteins may be involved in driving 
the composition of thrombus. The percentage of platelet vs fibrin components are 
thought to be different dependent on ischaemic time. A previous study investigated the 
composition of coronary thrombi aspirated from patients with acute myocardial 
infarction (AMI) [19]. They found that fibrin content increased from 48.4% in thrombi 
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that were collected less than 3 h from symptom onset to 66.9% in those that were 
collected after 6 h, whereas platelet content decreased from 24.9% to 9.1%.  
Another important limitation of our current analysis is that the analytical design does 
not completely take into account the angiographic findings. Given that generation of 
STEMI/NSTEMI ECGs depends on the coronary anatomy, collateral circulation and 
site of the culprit lesion [4,20], a future analytical approach should consider such 
factors.  ECG classification should be set aside to allow a comparison of those patients 
with acute total occlusion of culprit arteries with patients presenting with non/partial 
occlusions. Such a reclassification of ACS diagnosis of course would require future 
validation to assess and compare the accuracy with the current gold standards; ECG, 
patient history and cardiac Troponin. Until such validations are carried out the use of 
the protein panels reported in this study should be further investigated with regards to 
improving the confidence in ECG interpretation by clinical staff. This could be useful 
given the reports of clinicians being sub-optimal in ECG interpretation [5,6].  
 
Overall this study reports a protein biosignature that can accurately classify ACS and 
we believe that our study design has allowed us to uncover proteins within this 
biosignature that are specific for CAD.  Future work is now required however to explore 
the diagnostic potential of these biomarkers and to decipher if thy may augment ECG 
interpretation.  
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Table 1: Patient Characteristics 
           ACS     
 Coronary Artery Disease (CAD)   
 STEMI 
(n=7) 
NSTEMI 
(n=77) 
UA 
(n=21) 
ELECTIVES 
(n=102) 
Low 
Risk 
(n=81) 
P Value 
Demographics       
Age (years) 65 67 64 66 41 p<0.001 
Male (n; %) 5;71 66;86 17;81 79;77 17;21 p<0.001 
Female (n; %) 2;29 11;14 4;19 23;23 64;79 p<0.001 
Weight (Kg) 120 87 86 86 74 p<0.001 
Height (cm) 168 172 165 170 167 ns 
BMI (Kg/m2) 30 29 29 35 27 ns 
Current smokers (n; %) 2;29 23;30 2;10 11;11 1;1 p<0.001 
Clinical Variables       
Total Cholesterol (mmol/L) 5.4 4.2 4.3 5.8 5 ns 
LDL Cholesterol (mmol/L) 2.7 1.2 2.3 2.1 1.6 p<0.001 
 HDL Cholesterol (mmol/L) 1.2 2.3 1.2 1.2 2.9 p<0.001 
 TG (mmol/L) 1.2 1.9 1.7 1.7 1 ns 
 CRP (mg/L) 9.6 18 2.9 6.6 2.4 p<0.001 
Troponin positive (%) 7;100 77;100 0;0 0;0 0;0 p<0.001 
Co-morbidities       
Hypertension (n;%) 3;43 44;57 2.9 57;56 5;6 p<0.001 
Diabetes (n;%) 0;0 14;18 4;19 19;19 0;0 p<0.001 
GFR<60ml/min (n;%) 0;0 25;32 3;14 13;13 0;0 p<0.001 
Previous MI 1;14 19;25 5;24 43;42 0;0 p<0.001 
Previous PCI 1;14 14;18 8;38 45;44 0;0 p<0.001 
 
 
 
 
 
Table 2: STEMI and NSTEMI patient characteristics  
 STEMI 
(n=6) 
NSTEMI  
(n=6) 
 
P Value 
Demographics     
Age (years) 62 61  ns 
Male (n; %) 4;67 3;50  ns 
Weight (Kg) 84 87  ns 
Height (cm) 168 174  ns 
BMI (Kg/m2) 29 29  ns 
Current smokers (n; %) 2;33 2;33  ns 
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Clinical Variables     
Total Cholesterol (mmol/L) 5.6 4.5  ns 
LDL Cholesterol (mmol/L) 2.5 2.8  ns 
 HDL Cholesterol (mmol/L) 1.2 0.9  ns 
 TG (mmol/L) 1.1 1.8  ns 
 CRP (mg/L) 43 72  p<0.001 
Peak Troponin 1817 639  p<0.001 
Symptom onset to admission>4 days (n;%) 6;100 6;100  ns 
Time from symptom to blood sample >1 day 
(n;%) 
5;83 2;33  ns 
Co-morbidities     
Hypertension (n;%) 3;50 2;33  ns 
Diabetes (n;%) 0;0 1;17  ns 
GFR>60ml/min (n;%) 6;0 3;50  ns 
Previous MI 1;17 1;17  ns 
Previous PCI 2;33 1;17  ns 
 
 
 
 
